Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
← catalyst calendarNCT06465810 · readout in 1,958 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With ICON plc.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,850estimated
Sites
89
Countries
Canada, China, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-25 | actual | When the study began enrolling |
| Primary completion | 2031-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-29 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Transthyretin Amyloidosis
- ATTR-CM
- ATTRv-PN
- ATTR
- ATTR-Mixed
- hATTR
Intervention
- Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Primary outcomes
what the primary-completion date above is the date OFDemographic characteristics (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Treatment patterns (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Clinical characteristics (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Findings from biopsy (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Findings from Cardiovascular magnetic resonance imaging (CMR) (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Findings from Bone tracer cardiac scintigraphy (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Findings from Echocardiography (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
ECG variables (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Sural nerve and tibial nerve amplitude (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Biomarker results (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Urine test results (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Clinical manifestations (signs and symptoms) of ATTR amyloidosis (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
36-Item Short Form Health Survey Version 2 (SF-36v2) Physical Component Summary score (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Norfolk Quality of Life-Diabetic Neuropathy total score (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
New York Heart Association (NYHA) classification (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
National Amyloidosis Centre (NAC) ATTR staging or Mayo staging (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Familial amyloid polyneuropathy (FAP) (Coutinho) staging (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Polyneuropathy disability (PND) score (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Left Ventricular Ejection Fraction (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
6-minute walk test (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Charlson comorbidity index (CCI) and CCI components (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Other comorbidities of interest (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Healthcare resource utilization (overall and in patients initiating a treatment with eplontersen)
measured From time of enrollment for up to 7 years
Mortality (overall and in patients initiating a treatment with eplontersen)
measured Throughout study follow-up (up to 7 years)
Liver Disease and Live Transplant
measured From time of Enrollment for up to 7 Years
Publications
- PMID 40108078 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed